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Summary
 
Terminal sialic acids on cell surface glycoconjugates can carry 9-
 
O
 
-acetyl esters. For technical
reasons, it has previously been difficult to determine their precise distribution on different cell
types. Using a recombinant soluble form of the Influenza C virus hemagglutinin-esterase as a
probe for 9-
 
O
 
-acetylated sialic acids, we demonstrate here their preferential expression on the
CD4 T cell lineage in normal B10.A mouse lymphoid organs. Of total thymocytes, 8–10%
carry 9-
 
O
 
-acetylation; the great majority of these are the more mature PNA
 
2
 
, HSA
 
2
 
, and
TCR
 
hi
 
 medullary cells. While low levels of 9-
 
O
 
-acetylation are seen on some CD4/CD8 dou-
ble positive (DP) and CD8 single positive (SP) cells, high levels are present primarily on 80–
85% of CD4 SP cells. Correlation with CD4 and CD8 levels suggests that 9-
 
O
 
-acetylation ap-
pears as an early differentiation marker as cells mature from the DP to the CD4 SP phenotype.
This high degree of 9-
 
O
 
-acetylation is also present on 90–95% of peripheral spleen and lymph
node CD4 T cells. In contrast, only a small minority of CD8 T cells and B cells show such lev-
els of 9-
 
O
 
-acetylation. Among mature peripheral CD4 T lymphocytes, the highly 
 
O
 
-acetylated
cells are Mel 14
 
hi
 
, CD44
 
lo
 
, and CD45R(exon B)
 
hi
 
, features typical of naive cells. Digestions with
trypsin and 
 
O
 
-sialoglycoprotease (OSGPase) and ELISA studies of lipid extracts indicate that the
9-
 
O
 
-acetylated sialic acids on peripheral CD4 T cells are predominantly on O-linked mucin-
type glycoproteins and to a lesser degree, on sialylated glycolipids (gangliosides). In contrast,
sialic acids on mucin type molecules of CD8 T cells are not 
 
O
 
-acetylated; instead these mole-
cules mask the recognition of 
 
O
 
-acetylated gangliosides that seem to be present at similar levels as
on CD4 cells. The 9-
 
O
 
-acetylated gangliosides on mouse T cells are not bound by CD60 anti-
bodies, which recognize 
 
O
 
-acetylated gangliosides in human T cells. Tethering 9-
 
O
 
-acetylated
mucins with the Influenza C probe with or without secondary cross-linking did not cause acti-
vation of CD4 T cells. However, activation by other stimuli including TCR ligation is associ-
ated with a substantial decrease in surface 9-
 
O
 
-acetylation, primarily in the mucin glycoprotein
component. Thus, 9-
 
O
 
-acetylation of sialic acids on cell surface mucins is a novel marker on
CD4 T cells that appears on maturation and is modulated downwards upon activation.
 
S
 
ialic acids (Sia)
 
1
 
 are a family of 9-carbon negatively
charged sugars usually found at terminal positions of
mammalian cell surface sugar chains. Sias can be attached to
underlying glycoconjugates in a variety of linkages, and modi-
fied in many different ways (1, 2). These modifications
were once thought to be rare, species-specific curiosities.
However, recent evidence has shown that some modifica-
tions are more widely distributed than previously thought
(2, 3). For example, Sias often carry 
 
O
 
-acetyl substitutions
at the C-7 or C-9 positions (1–4). Since 
 
O
 
-acetyl esters at
C-7 position will spontaneously migrate to the C-9 posi-
tion at physiologic extracellular pH (5, 6), 9-
 
O
 
-acetylated
Sias predominate on cell surface glycoconjugates (7). Iden-
tification of the cells and sialoglycoconjugates bearing 9-
 
O
 
-
acetylation has been technically challenging, since these es-
ters are often present on only a fraction of total sialic acids,
and biochemical purification steps can be accompanied by
varying losses of 
 
O
 
-acetylation.
Several studies have shown that 9-
 
O
 
-acetylation can af-
fect the biological properties of the underlying molecules.
These esters are commonly seen on cells of neuroectoder-
 
1
 
Abbreviations used in this paper:
 
 BM, bone marrow; CHE, influenza C vi-
rus hemagglutinin-esterase protein with the fusion peptide eliminated by
mutation; CHE-Fc, chimeric protein made of CHE and the Fc portion of
human IgG
 
1
 
; CHE-FcD, DFP treated CHE-Fc (esterase activity irrevers-
ibly inactivated); DFP, diisopropylfluorophosphate; DN, double negative;
DP, double positive; HSA, heat stable antigen; OSGPase, O-sialoglyco-
protease; PNA, peanut agglutinin; Sia, sialic acids; SP, single positive;
TBS, Tris-buffered saline.
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9-
 
O
 
-acetylation in CD4 Cells
 
mal origin and seem to have a role in the migration of de-
veloping neurons in the embryonic brain (8, 9). Abrogation
of 9-
 
O
 
-acetylation can deleteriously affect development in
transgenic mice (10). This modification is also involved in
specific recognition of cells by Influenza C virus and corona-
viruses (11–13), can modulate activation of complement by
the alternate pathway (14, 15), and can mask ligands for I-type
lectins that mediate cell adhesion via sialylated ligands e.g.,
CD22 on B cells (16) and sialoadhesin on tissue macro-
phages (15, 17).
Taking advantage of the binding and catalytic property
of the Influenza C virion’s hemagglutinin-esterase (CHE)
protein for 9-
 
O
 
-acetylated sialic acids, we had earlier engi-
neered a recombinant soluble form of the extracellular do-
main of CHE (CHE-Fc) with a human IgG
 
1
 
 Fc region
fused to the carboxyl end (3). Treatment of this molecule
with diisopropylfluorophosphate (DFP) selectively abro-
gates its esterase activity (CHE-FcD) while preserving the
binding property (3, 18). Thus, the probe is a bifunctional
tool for either selectively removing (CHE-Fc) or specifi-
cally detecting (CHE-FcD) 9-
 
O
 
-acetyl esters. In studying
mouse peripheral leukocytes with this probe, we noted high
binding to CD4 T cells and much less binding to CD8 T cells.
Apart from the CD4 molecule itself, we are unaware of any
other cell surface marker that is selectively expressed on
CD4 cells in comparison to CD8 cells. We therefore de-
cided to further delineate the presence and distribution of
9-
 
O
 
-acetylated sialic acids on cells of the murine T cell lin-
eage. Indeed, we find that 9-
 
O
 
-acetylation of sialic acids is
a novel cell surface marker which appears during differenti-
ation of CD4 single positive T cells in the thymus, persists
at high levels on these cells in the periphery, and decreases
in expression upon cellular activation. We have also used
the enzymes trypsin and O-sialoglycoprotease (OSGPase)
(19) to explore the distribution of these modified sialic ac-
ids on the different classes of glycoconjugates found on
CD4 cell surfaces. The latter enzyme is particularly useful
because it selectively cleaves mucin-type glycoproteins with
clustered sialylated O-linked sugar chains (20), such as
CD43 and some CD45 forms (21).
 
Materials and Methods
 
Mice.
 
4–6-wk-old B10.A mice were purchased from The
Jackson Laboratories (Bar Harbor, ME). All studies were done
with freshly isolated cells from 6–8 wk old B10.A mice.
 
Antibodies and Probes.
 
Fluoresceinated anti-human IgG sec-
ondary antibodies were used to detect the binding of the CHE-
FcD probe to the cells. FITC, phycoerythrin or tricolor conju-
gated rat monoclonal antibodies against murine CD4 and CD8
were purchased from Caltag Laboratories (San Francisco, CA).
Binding of biotinylated rat monoclonal antibodies (from Phar-
Mingen, San Diego, CA) against murine CD25, CD69, CD5, Mel
14, CD45RB, CD43, and Pgp-1 was detected using appropriately
conjugated streptavidin in all flow cytometric assays. The anti-
CD43 monoclonal antibody S7 recognized the 115-kD isoform
of CD43. The 23G2 clone of the anti CD45RB monoclonal an-
tibody was used in all FACS
 
Ò
 
 staining and Western blots. Binding
of anti-CD45RB and CD43 antibodies to proteins in Western blots
was detected using Neutravidin-alkaline phosphatase conjugate
purchased from Pierce (Rockford, Illinois). The anti-mouse CD3
hamster hybridoma 2C11was prepared in ascites form and used to
stain cells expressing the TCR. The rat anti–mouse heat stable anti-
gen (HSA) was used as a culture supernatant from the J11D hy-
bridoma. JONES antibody (a mouse IgM recognizing 9-
 
O
 
-acety-
lated G
 
D3
 
) (9) was purchased from Sigma Chem. Co. (St. Louis,
MO) while 27A, a mouse IgG (22) with the same specificity as
JONES, was obtained from cell culture supernatants of hybrid-
omas provided by M. Farquhar (UCSD). The soluble chimeric
protein CHE-Fc, consisting of the extracellular domain of influ-
enza C hemagglutinin-esterase fused to the Fc portion of human
IgG
 
1
 
 was generated and characterized as described (3). The modi-
fied form CHE-FcD was generated by treating CHE-Fc with 1 mM
DFP to inactivate the esterase activity as described (3). CHE-Fc
specifically releases 9-
 
O
 
-acetyl esters from Sias (i.e., it functions as
an esterase), whereas CHE-FcD specifically recognizes and binds
to 9-
 
O
 
-acetylated Sias (3). Fluoresceinated peanut agglutinin lectin
(PNA) was obtained from EY Laboratories Inc. (San Mateo, CA).
 
Flow Cytometric Analysis of 9-O-Acetylation on Cells.
 
The expres-
sion of cell surface 9-
 
O
 
-acetylated sialic acids was examined by
flow cytometric analysis on a FACScan
 
Ò
 
 machine. Freshly ob-
tained live cells from B10.A mouse thymus, lymph nodes and
spleen were prepared after hypotonic lysis of RBCs and 1 
 
3
 
 10
 
6
 
cells were washed and suspended in ice cold PBS with 1% bovine
serum albumin and 0.1% sodium azide (staining buffer). The
CHE-FcD probe was allowed to bind to the cells after being im-
munocomplexed with FITC or phycoerythrin conjugated goat anti–
human secondary antibody. CHE-FcD (3 
 
m
 
g) was incubated
with a 1 in 100 dilution of the secondary antibody at 4
 
8
 
C over-
night. This pre-complexing step increases the overall avidity of
the probe towards 9-
 
O
 
-acetylated sialic acids. The CHE-FcD 
 
1
 
anti-human IgG Fc immunocomplex was allowed to bind to the
cells for 2 h on ice. For all double and triple-color stainings, the
CHE-FcD probe was allowed to bind to the cells before staining
with the remaining antibodies for 30 min at room temperature.
The CHE-Fc was used under identical conditions as a negative
control for CHE-FcD binding. In studies where cells had to be
de-
 
O
 
-acetylated before staining, CHE-Fc was used at a final con-
centration of 10 
 
m
 
g/ml in a volume of 50 
 
m
 
l of staining buffer
containing 3–5 
 
3
 
 10
 
6
 
 cells and incubated at 37
 
8
 
C for 1 h. For
trypsinization, cells were incubated in 0.1% trypsin with 0.5 mM
EDTA in Hank’s balanced salt solution for 1 h in a 37
 
8
 
C water
bath, then washed twice with cold PBS before staining. The loss
of anti-CD4 binding was used to confirm trypsin activity. For
treatment with OSGPase (Cedarlane Laboratories Ltd., Ontario,
Canada) 5 
 
3
 
 10
 
6
 
 live cells in 100 
 
m
 
l of staining buffer were incu-
bated with 5 
 
m
 
l of the reconstituted enzyme at 37
 
8
 
C for 1 h. Cells
were then washed twice with cold PBS before staining. Decrease
in CHE-FcD binding to murine erythroleukemia cells following
OSGPase treatment was used as a positive control for this enzyme
(data not shown). Following staining, cells were washed with ex-
cess staining buffer and fixed in PBS containing 1% formaldehyde
(fixing buffer). Stained fixed cells were kept in dark at 4
 
8
 
C and
analyzed by flow cytometry the same day.
 
Purification of CD4 T Cells.
 
Fresh mouse lymphocytes from
either spleen or lymph nodes were prepared after hypotonic lysis
of RBCs and separation of dead cells by Ficoll Hypaque density
centrifugation. Cells were stained with rat anti–mouse CD4 con-
jugated with magnetic beads from Miltenyi Biotec, Inc. (Auburn,
CA). This antibody was used at a final dilution of 1:10 to stain 10
million live cells in a volume of 100 
 
m
 
l on ice for 30 min. CD4
cells were then separated using a magnetic cell sorter (MACS). 
1999
 
Krishna and Varki
The purity of the sorted population, confirmed by flow cytome-
try, was 
 
z
 
90%. In some cases, CD4 cells were separated on a
Becton Dickinson FACSorter
 
Ò
 
 after staining with tricolor conju-
gated rat anti–mouse CD4.
 
Activation of T Cells.
 
Either total cells or FACSorted
 
Ò
 
 CD4 T
cells from mouse lymph nodes were activated in EHAA medium
(from GIBCO BRL, Gaithersburg, MD) supplemented with 10%
heat inactivated FBS, 1% 
 
l
 
-glutamine, 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME, 1%
penicillin and streptomycin and 10 mM Hepes (referred hereafter
as EHAA growth medium) at 37
 
8
 
C in a humidified atmosphere
with 5% CO
 
2
 
 in the presence of 2 ng per ml of PMA and 300 nM
ionomycin. Typically 5 
 
3
 
 10
 
6
 
 cells were cultured in 2 ml of me-
dium per well in a 6-well plate. Aliquots of cells were then ana-
lyzed by flow cytometry for levels of expression of 9-
 
O
 
-acetyla-
tion on subsequent days. In other experiments, either total lymph
node cells or 0.5 
 
3
 
 10
 
6
 
 CD4 T cells mixed with 2.5 
 
3
 
 10
 
6
 
 mito-
mycin-treated syngenic mouse spleen cells in 200 
 
m
 
l of EHAA
growth medium were placed in 96-well plates coated with 50 ng
2C11 mAb to cross-link the TCR complex and activate the cells.
 
Studies to Check for CHE-FcD Induced Activation.
 
CHE-FcD
probe in amounts ranging from 0.5 to 3 
 
m
 
g was allowed to bind
overnight at 4
 
8
 
C on to Staph protein A–coated 96-well plates.
0.5 
 
3
 
 10
 
6
 
 lymphocytes from peripheral lymph nodes were then
incubated with 200 
 
m
 
l of EHAA growth medium per coated well.
Triplicate wells were set up for each amount of CHE-FcD. An
identical setup with CHE-Fc was done as a negative control. 2 d
later, the cells were pulsed with 1 
 
m
 
Ci/well of [
 
3
 
H]thymidine and
the following day the cells were harvested onto glass fiber filter-
mats. The amount of incorporated radioactivity was determined
on a betaplate reader (Wallac 1205; Wallac Inc., Gaithersburg, MD).
Cross-linking with 2C11 as described above was done as a posi-
tive control. In another set of experiments, CHE-FcD was al-
lowed to bind to CD4 T cells in solution without cross-linking its
ligands. Assays were once again done in triplicate for each
amount of CHE-FcD in 96-well flat bottomed plates with 0.1 
 
3
 
10
 
6
 
 purified CD4 cells and 0.5 
 
3
 
 10
 
6
 
 mitomycin-treated syngenic
mouse splenic cells added in 200 
 
m
 
l of EHAA growth medium
per well. The final concentration of CHE-FcD in the wells varied
from 10–100 
 
m
 
g/ml. Similar amounts of CHE-Fc were used as a
negative control. To see whether CHE-FcD binding to cells ei-
ther potentiated or diminished the response to other activating
stimuli, cells were stimulated pharmacologically using PMA or by
cross-linking the TCR with an anti-CD3 antibody 2C11. The
stimulation was carried out using increasing doses of the stimulat-
ing agent over a range that gave concomitant increases in activa-
tion. CHE-Fc or CHE-FcD (50 
 
m
 
g/ml final) was used in combi-
nation with the varying amounts of PMA or anti-CD3, and
compared to cells being activated in the absence of CHE-Fc or
CHE-FcD. Cells were incubated for 4 d before being pulsed with
1 
 
m
 
Ci/well of [
 
3
 
H]thymidine. The incorporated radioactivity was
quantitated as described earlier.
 
Extraction of Glycoproteins and Glycolipids.
 
Membrane proteins
were prepared from spleen and lymph node cells remaining after
hypotonic lysis of red blood cells. The cells were washed with 1
 
3
 
PBS three times followed by hypotonic lysis in the presence of 20
mM Hepes, pH 7.4, and a cocktail of protease inhibitors. They
were disrupted by nitrogen cavitation and spun at 500 g at 48C to
remove nuclei and unbroken cells. The cloudy supernatant was
then spun at 100,000 g at 48C to obtain a total membrane pellet.
The membranes were then extracted with 1% Triton X-100 in
13 Tris-buffered saline, pH 8.0 (TBS), separated from the mem-
brane debris by recentrifugation at 100,000 g, and the protein
concentration was determined by Bradford assay. Typically 600–
700 mg of membrane proteins could be obtained from 3.5 3 108
cells and were adjusted to z1–2 mg/ml for use in Western blots
and immunoprecipitation assays. To purify gangliosides, the
washed cell pellets were sequentially extracted by 10–20 vol
CHCl3/MeOH (2:1, 1:1, and 1:2 vol/vol), using brief homog-
enization. The extracts were pooled, dried down, and brought up
in CHCl3/MeOH/water in the ratio of 4:8:5.6. After phase sepa-
ration, the gangliosides were enriched in the hydophilic upper
phase. This was dried down, resuspended in methanol, and kept
at 2208C until use.
ELISA Plate Assay for 9-O-Acetylation on Gangliosides. Total gan-
glioside extracts prepared as above were studied by lipid ELISA as
described previously (23). In brief, lipids were applied to the plates
in 45% methanol, allowed to dry, and then blocked with 5% BSA
in PBS overnight. The effects of base (de-O-acetylation) on reac-
tivity were assessed by treatment with 0.1 M NaOH at 48C for 30
min (these conditions do not cause any loss of bound ganglio-
sides). After treatment, the plates were extensively washed with
PBS, blocked with 2% BSA in PBS for 1 h, and then incubated
with CHE-FcD (20 mg/ml) for 2 h. After washing three times with
1% BSA, a horseradish peroxidase-conjugated goat anti–mouse IgG
was added (at 1:1,000 dilution) for 1 h. After washing further, the
reaction was developed as described above. Background levels
determined with the secondary antibody alone were subtracted.
Western Blot Assays. Membrane proteins were extracted as
described above from total lymphocytes harvested from mouse
spleen and lymph nodes. SDS-PAGE was done under reducing
conditions in 7.5% gels. The electrophoresed material was trans-
ferred to nitrocellulose membranes, blocked with 5% bovine se-
rum albumin in 13 TBS for 2 h at room temperature and then
incubated with the primary probe overnight at 48C on a rocking
platform. CHE-FcD was used at a concentration of 5 mg/ml and
the biotinylated monoclonals S7 (anti-CD43 115-kD isoform) and
23G2 (anti-CD45RB) were used at a concentration of 1 mg/ml
in 1X TBS containing 1% bovine serum albumin. After this the
membranes were washed thrice with 0.05% Tween 20 in 13
TBS for 30 min and incubated with the secondary reagents for 1 h
at room temperature. Bound biotinylated antibodies were de-
tected with 1:5,000 dilution of Neutravidin-alkaline phosphatase
(Pierce Chem. Co., Rockford, IL) and CHE-FcD binding was
assayed with 1:2,500 dilution of goat anti–human Fc conjugated
with alkaline phosphatase (Bio-Rad, Richmond, CA). The mem-
branes were washed thrice with 0.05% Tween 20 in 13 TBS for
30 min and then with 13 TBS and put in alkaline phosphatase
buffer (pH 9.5) before adding the substrates NBT/BCIP at a 1:
100 dilution. The reaction was allowed to progress for 5–15 min
before washing with water and drying.
Selective Precipitation of 9-O-Acetylated Glycoproteins from Mem-
brane Extracts. 100–150 mg of the membrane protein extract was
first precleared with protein A–Sepharose beads by end over end
rolling at 48C for 2 h. Meanwhile, 75 mg of CHE-FcD was al-
lowed to complex with 50 ml of protein A–sepharose by end over
end rolling at 48C for the same length of time. The whole mix-
ture was then incubated overnight with the precleared sample in
a volume of 500 ml with end over end rolling at 48C. The beads
were then spun, washed in TBS, pH 7.4 and 6.8, successively and
boiled in SDS sample buffer with 2-mercaptoethanol. The eluted
proteins were loaded on SDS-PAGE gel and probed with anti-
CD45RB and anti-CD43 monoclonals as described here. The
CHE-Fc molecule served as a negative control for the proteins
specifically bound by CHE-FcD. The immunoprecipitates were also
reprobed with CHE-FcD to confirm their reactivity to check the
percentage of total 9-O-acetylated proteins that was precipitated.2000 9-O-acetylation in CD4 Cells
Results
9-O-Acetylation of Sias on the Cell Surface of Mature Murine
Thymocytes. Flow cytometry analysis of dispersed thymocytes
after CHE-FcD staining showed that 8–10% have surface
9-O-acetylation (Fig. 1 A, middle). Positively staining cells
are very heterogenous with respect to their degree of
9-O-acetylation in a range of z3 logs of fluorescence in-
tensity. Double-color analysis with PNA and CHE-FcD
showed that almost all of the 9-O-acetyl positive cells have
the more mature PNA2 phenotype expected of medullary
thymocytes (Fig. 1 B). This fits with our previous study, in
which staining of murine thymus sections with the CHE-
FcD probe was noted predominantly in the medullary re-
gion (16). The specificity of CHE-FcD staining was con-
firmed by the markedly lower binding of CHE-Fc (Fig. 1 A,
left), the residual staining is probably because cells with very
high 9-O-acetylation can give a weak signal even with the
esterase-active probe (3). Finally, binding with CHE-FcD
was substantially abrogated when cells were treated with
CHE-Fc esterase before staining (Fig. 1 A, right). In most of
the subsequent studies, these CHE-Fc controls were not
routinely done.
9-O-Acetylation of Sias in the Thymus Is Expressed Predomi-
nantly on a Subset of Mature CD4 Cells. These results show
that cell surface 9-O-acetylation is predominantly on the
more mature population of murine thymocytes. While the
degree of 9-O-acetylation on thymocytes ranges over 3 log
scales of fluorescence intensity (Fig. 1 A, middle), we no-
ticed that the total percentage of CHE-FcD1 thymocytes
tended to correlate best with the percentage of CD4 single
positive (SP) cells in the same preparation. Indeed, upon
three-color analysis of the 9-O-acetyl1 cells, a large frac-
tion of these were found to be CD41 SP cells (Fig. 2). In
contrast to a high intensity of staining in CD41 SP cells,
the degree of 9-O-acetylation was low in the other cell
types, except for some enrichment in the CD42CD82
double negative (DN) cells. Further analyses showed that
9-O-acetylation is present on z75% of all the CD41 SP
cells, 40% of the DN cells and only 8% of CD81 SP cells
(Fig. 3). The density of 9-O-acetylation on the 9-O-
acetyl1 DN cells is relatively lower than that on the CD41
SP cells (Fig. 3). Given the heterogeneity of DN thymo-
cytes with respect to maturity (24), we cannot be certain
which subpopulation of these cells are 9-O-acetylated. Re-
gardless, the lowest amount of 9-O-acetylation was seen in
the CD41CD81 double positive (DP) thymocytes (1–2%).
Thereafter, there is a progressive increase in 9-O-acetyla-
Figure 1. Expression of 9-O-acetylation on murine thymocytes. (A) Single-color flow
cytometry showing cell surface 9-O-acetylation on total thymocytes. Thymocytes were
stained with CHE-FcD or CHE-Fc as indicated within the panels, followed by phycoeryth-
rin-conjugated goat anti–human IgG. One aliquot was pretreated with CHE-Fc to re-
move 9-O-acetyl groups before staining with CHE-FcD. The dashed line indicates the
background level of staining with the secondary antibody alone. (B) Double-color flow cy-
tometry comparing PNA and CHE-FcD staining on total thymocytes. Thymocytes were
stained with CHE-FcD followed by phycoerythrin-conjugated goat anti–human IgG and
FITC-conjugated PNA. Quadrant boundaries were determined based on background
staining profiles seen with phycoerythrin-conjugated goat anti–human IgG alone or FITC-
conjugated PNA in the presence of 0.2 M galactose.2001 Krishna and Varki
tion as the cells mature from the DP stage through the
CD41 SP stage. In contrast, the cells progressing towards
the CD81 lineage show minimal increase. Cells in the CD41
SP subset varied in levels of 9-O-acetylation; these levels
correlated inversely with CD8 levels (Fig. 3). Thus, in-
creasing cell surface 9-O-acetylation is correlated with the
progression of maturation of CD41 thymocytes.
Association of the 9-O-Acetyl1 Phenotype with other Thy-
mocyte Markers in the CD41 Lineage. CD41 thymocytes were
selectively gated to study the relationship of 9-O-acetyla-
tion with other well defined traits that mark the progression
of cells from DP to CD41CD82 stage (Fig. 4). Increasing
9-O-acetylation was correlated with increasing expression
of TCR and decreasing levels of HSA, indicating that these
CD4 cells have been committed for further maturation after
the DP stage. Thymocyte maturation to a CD41 SP stage oc-
curs with upregulation of CD5 and CD69, both of which
are responsive to signals delivered through the TCR during
positive selection (25-27). While the increase in CD5 ex-
pression remains stable, CD69 is an early T cell activation
marker, being initially high during the CD4hi CD8lo stage
and decreasing to lower levels in the CD41 SP cells. Most
transitional cells between the DP and the CD4 SP stages
and almost all the CD41 SP cells have a CD5hi phenotype,
which fits our observation that most of the 9-O- acetyl1 cells
are also CD5hi (Fig. 4). The 9-O-acetylloCD5lo cells are
most probably the transitional cells. Although more of the 9-
O-acetylhi cells are CD692, the 9-O-acetyl1 cells as a
whole appear to be equally divided with respect to CD69
expression, implying that 9-O-acetylation does not identify
cells purely based on their activation state. Together, these
results show that CD41 thymocytes are the major carriers
of 9-O-acetylation, and that expression progressively in-
creases with maturation in the thymus.
9-O-Acetylation Is Also Enriched on CD4 T Cells in Periph-
eral Lymphoid Organs. Varying levels of 9-O-acetylation were
found on lymphocytes from spleen and lymph nodes. In dif-
ferent preparations from spleen and lymph node, the percent-
age of 9-O-acetylated CD4 T cells varied from 85–90%.
Although 25–30% of CD81 T lymphocytes, and 5–10% of
CD42CD82 lymphocytes also had this phenotype, the de-
Figure 2. CD4 and CD8 distribution on total thymocytes and on 9-O-
acetyl1 cells. Three-color flow cytometry was done after staining with
CHE-FcD, anti-CD4, and anti-CD8. The 9-O-acetyl positive cells were
gated to obtain a selective CD4/CD8 profile. Since CD8 SP and CD42
CD82 DN cells constitute a low percentage of total thymocytes, 100,000
total events were acquired to analyze the small percentage of total 9-O-
acetyl1 thymocytes.
Figure 3. Progressive increase
in 9-O-acetylation during matu-
ration of CD41 cells. Three-
color flow cytometry was done
after staining with CHE-FcD,
anti-CD4, and anti-CD8, as in
Fig. 2. Individual gates (R1-R8)
delineate cells with progressing
maturity from the CD42CD82
DN to CD41CD81 DP stage to
the CD41CD82 and CD42
CD81 SP stages. 100,000 total
events were acquired so that sig-
nificant number of cells within
the indicated regions could be
gated. The percentage of 9-O-
acetyl1 cells within each region
was determined based on the
background staining observed
with phycoerythrin-conjugated
goat anti–human IgG.2002 9-O-acetylation in CD4 Cells
gree of 9-O-acetylation on these cells was markedly lower
than on CD4 T cells. Correlation of CHE-FcD binding on
CD4 T cells with other markers shows that in both spleen and
lymph nodes the 9-O-acetylated cells are Mel14hi, Pgp1
(CD44)lo and CD45R(exonB)hi (Fig. 6). Indeed, CD4 cells
with the phenotype Mel141, CD45RB1 and CD442 are
almost all 9-O-acetylated, indicating that high 9-O-acetyla-
tion is a marker of naive T cell phenotype (28–30).
Distribution of Cell Surface 9-O-Acetylation among Glycopro-
teins and Glycolipids. Trypsinization of thymocytes caused
partial loss of 9-O-acetylation in most of the positive cells
(Fig. 7 A, bottom). Likewise, when FACSÒ-sorted CD41 SP
cells were trypsin-treated, there was a significant decrease
in 9-O-acetylation (nearly a fivefold decrease in mean fluo-
rescence intensity). Most glycoproteins are expected to be
trypsin sensitive, while the trypsin-resistant 9-O-acetylated
glycoconjugates are likely to be sialylated glycolipids (gan-
gliosides). One important subset of cell surface glycopro-
teins are mucins with clustered sialylated O-linked oligosac-
charides (which includes CD43 and some isoforms of CD45)
(31, 32). These can be selectively eliminated by the enzyme
OSGPase (19), an endopeptidase that will only cleave mu-
cins (20, 21). Upon treatment of thymocytes with OSGPase
(Fig. 7 A, middle), there was a marked decrease in 9-O-
acetylation (nearly a fivefold decrease in mean fluorescence
intensity) indicating that many of the 9-O-acetyl groups are
on Sias attached to O-linked oligosaccharides of mucin-type
glycoproteins (murine erythroleukemia cells (15) served as
positive controls for this enzyme, data not shown). The
substantial loss of the high 9-O-acetylated CD41 SP cells
with OSGPase treatment indicates that mucin-type glycopro-
teins are the major carriers for 9-O-acetylation in these
cells.
Similar trypsin and OSGPase treatments done on puri-
fied peripheral CD4 T cells from the spleen and lymph
nodes also indicates that most of the 9-O-acetylated glyco-
proteins are of the O-linked mucin-type (Fig. 7 B, left, show-
Figure 4. Relationship of 9-O-acetylation to expression of TCR,
HSA, CD69 and CD5 on CD41 thymocytes. Three-color staining was
done with anti-CD4 and CHE-FcD along with either anti-CD3, J11D
(anti-HSA), anti-CD69 or anti-CD5 as the third color. Binding of anti-
CD3 mAb 2C11 was detected using phycoerythrin-conjugated goat anti–
hamster IgG and mAb J11D was detected by FITC conjugated donkey
anti–rat IgG. Anti-CD69 and anti-CD5 were directly conjugated to FITC
and anti-CD4 to tricolor reagent. Only CD41 thymocytes were gated to
show the dot plots relating 9-O-acetylation with other thymocyte mark-
ers. Quadrant boundaries were determined based on the background
staining profiles obtained by the secondary antibodies for each axis.
Figure 5. Association of 9-O-
acetylation with CD4 cells
among peripheral lymphocytes.
Cells from peripheral lymph
nodes or spleen of a 8-wk-old
B10.A mouse were three color
stained with anti-CD4, anti-
CD8 and CHE-FcD and sub-
jected to flow cytometry. 9-O-
acetylation profiles on CD4 and
CD8 positive cells were obtained
by gating on the respective cells
on a CD4/CD8 dot plot. The
background (dashed line) repre-
sents staining seen with the
CHE-Fc. The percentage posi-
tivity of the cell groupings dis-
played in the histograms is indi-
cated.2003 Krishna and Varki
ing a three- to fivefold decrease in the mean fluorescence
intensity of staining after enzyme treatment). However,
there is also a significant amount of trypsin- and OSGPase-
resistant 9-O-acetylation (Fig. 7 B, left). Indeed, the shift in
the profile upon protease digestion indicates that almost all
CD4 cells that have 9-O-acetylated glycoproteins may also
have 9-O-acetylated gangliosides. Notably, the CD8 mole-
cule was preserved after treatment with OSGPase, despite
the fact that it carries several scattered O-linked oligosac-
charides (data not shown). This provides an internal control
for the selectivity of the enzyme in cleaving only mucin-
type proteins with many clustered sialylated O-linked
chains.
To confirm that the residual staining after protease diges-
tion was due to 9-O-acetylated gangliosides, an ELISA as-
say with the CHE-FcD probe was done on the lipid ex-
tracts obtained from CD4 cells. The binding of the probe
to the lipids on the plate was abrogated by base treatment,
indicating the presence of 9-O-acetylated gangliosides in the
extracts (Fig 8). One of the better studied 9-O-acetylated
gangliosides is 9-O-acetylated GD3, which has recently
been shown to occur on human peripheral T cells as one of
the epitopes in the CD60 cluster (33). This molecule was
not detectable on mouse thymocytes or on mouse periph-
eral CD4 T cells using both JONES and 27A antibodies
(data not shown). However, these antibodies are highly spe-
cific for 9-O-acetylated GD3, and would not detect many
other 9-O-acetylated gangliosides. We therefore tried 8A2,
a mAb that recognizes certain other larger 9-O-acetylated
gangliosides in human melanoma cells (34). This antibody
was also unable to bind to mouse thymocytes and periph-
eral CD4 T cells (data not shown). There is also no correla-
tion between 9-O-acetylation and the presence or absence of
epitopes recognized by antibody SM3G11 (35, 36), which is
known to detect the mouse T cell ganglioside GD1c (data not
shown). These data suggest that while certain gangliosides
on murine CD4 cells constitute a significant proportion of
total 9-O-acetylated molecules, they must be structurally
distinct from those reported as CD60 markers on human
T cells.
Effect of CD4 Cell Activation on Cell Surface 9-O-Acetyla-
tion. Mature CD4 T cells from lymph nodes were puri-
fied and activated by anti-CD3 or by PMA/Ionomycin. The
activation phenotype was confirmed by looking for cell
surface activation markers such as CD25 on various days af-
ter activation ranging from day 2 up to day 13. CD4 cell
surface 9-O-acetylation showed nearly a two- to threefold
decrease by day 3 (Fig. 7 B, right). The residual 9-O-acety-
lation following activation is almost entirely refractory to
treatment with trypsin and OSGPase (Fig. 7 B, right), indi-
cating 9-O-acetylation is lost on mucin-type proteins, but
not on gangliosides. This is confirmed by direct analysis of
gangliosides from the activated cells (Fig. 8). There was no
correlation of 9-O-acetylation with expression of CD69,
CD25, CD45R(exonB), Mel14 or Pgp1 on any of the days
after activation (data not shown). Thus, 9-O-acetylation of
sialic acids on mucin-type glycoproteins appears to be a dis-
tinctive marker on CD4 T cells that is down-regulated upon
activation. In contrast, 9-O-acetylation of gangliosides per-
sists after activation.
Ligation of 9-O-Acetyl Groups on CD4 Cells Does Not Cause
Activation. CD60 antibodies are reported to be weakly mito-
genic to human peripheral blood mononuclear cells, and are
comitogenic with the phorbol ester PMA for purified rest-
ing T cells (37–39). Although murine T lymphocytes are
not CD601, the 9-O-acetyl groups can be ligated by CHE-
FcD. Lymphocytes from murine lymph nodes were cultured
on plates precoated with protein A–Sepharose and then
coated with increasing amounts of CHE-FcD. This cross-
linking of 9-O-acetylated molecules on the cell surface did
not result in any proliferation of cells, when followed over
the next few days (data not shown, there was also no prolifer-
ation with equivalent amounts of CHE-Fc or with an irrel-
evant chimera). Likewise, there was also no proliferative
response from purified CD4 T cells when the CHE-FcD
was used in a soluble form, in the presence of mitomycin
treated costimulatory cells (data not shown). Fig. 9 (top and
Figure 6. Association of other markers with 9-O-acetylation among
CD4 peripheral lymphocytes. Flow cytometry was done after three color
staining using anti-CD4 and CHE-FcD along with anti-Mel14, anti-Pgp1
or anti-CD45R(exonB). All peripheral T cell markers were used as biotin-
ylated antibodies and their binding was detected using streptavidin conju-
gated FITC. The data displayed here represents only CD41 gated cells.
Staining on each axis of the dot plot was determined after using the sec-
ondary fluorescent conjugated reagent alone without the primary anti-
body or probe.2004 9-O-acetylation in CD4 Cells
bottom) shows that soluble CHE-FcD in concentrations up
to 50 mg/ml neither potentiates nor inhibits T cell activa-
tion mediated either by PMA or by anti-CD3. The experi-
ment was done over a range showing a typical dose re-
sponse relationship to the stimulating agent to see if there
are any noticeable differences at submaximal doses of PMA
or anti-CD3. Taken together, the data indicate that ligating
the 9-O-acetyl groups accessible to the CHE-FcD chimera
does not result in cellular activation.
Sialomucins on CD8 T Cells Are Not 9-O-Acetylated, but They
Mask Recognition of 9-O-Acetylated Gangliosides by CHE-FcD.
The level of 9-O-acetylation detected on mature CD8 T
cells was considerably lower than on CD4 T cells. We con-
sidered the possibility that this might be due to differential
expression of sialylated substrates for 9-O-acetylation on the
respective cell types. Given the preponderance of 9-O-acety-
lated sialomucins on CD4 T cells we looked for their pres-
ence on CD8 T cells. As shown in Fig. 10 A, removal of
the sialomucins by OSGPase actually gives an increase in
CHE-FcD binding to CD8 T cells, i.e., the opposite of the
result with CD4 T cells. The same result was confirmed by
treating cells with trypsin (Fig. 10 A) or by a combination
of trypsin followed by OSGPase (data not shown) indicat-
ing that detection of protease resistant 9-O-acetylated gan-
gliosides can be masked by the presence of sialomucins on
CD8 cells. This pattern of increased CHE-FcD binding af-
ter trypsin or OSGPase treatment was also reproduced on
CD8 SP thymocytes (Fig. 10 B). These results demonstrate
the presence of sialomucins on CD8 T cells, and indicate that
unlike in CD4 cells, these molecules are not substrates for
9-O-acetylation.
CD43 and CD45R(exonB) Isoforms Represent Some of the
9-O-Acetylated Mucins. CD43 (leukosialin) and CD45 are
two major, well-characterized T cell surface glycoproteins
known to carry large amounts of O-linked oligosaccharides
with terminal sialic acids (31, 32, 40). Assuming that these
might be some of the mucin-like molecules carrying 9-O-
acetylation and/or masking CHE-FcD binding to ganglio-
sides, we looked for any difference in their levels on CD4
and CD8 cells. Both thymic and peripheral T cells express
high molecular weight isoforms of CD45, and the exon 5
(coding for RB) specified isoforms are relatively predomi-
Figure 7. Changes in CD4 cell surface 9-O-acetylation after trypsinization, OSGPase treatment or activation. (A) Thymocytes were treated with
trypsin or OSGPase and then washed before staining. Following OSGPase treatment, CD41 SP cells were gated on a CD4/CD8 dot plot to examine the
CHE-FcD staining profile (staining of CD4 and CD8 was unchanged by the OSGPase treatment, data not shown). To study the effect of trypsin on
CHE-FcD binding to CD41 SP cells, CD41 SP thymocytes were first FACSortedÒ after two-color staining with anti-CD4 and anti-CD8 antibodies,
prior to CHE-FcD staining. (B) CD4 cells from peripheral lymph nodes were purified by FACSortingÒ and treated with trypsin or OSGPase and then
washed before staining (left). One aliquot of these cells were activated by cross-linking with anti-CD3 on a 96-well plate; the profiles displayed in the
right panels represent gated CD4 cells from the third day after activation; similar patterns were seen thereafter for 10 d (data not shown). In each case, the
percentage positivity of the cells is shown within the histogram display, and background level of staining is represented by the dashed line.2005 Krishna and Varki
nant as compared to RA and RC specified isoforms (41,
42). Amongst various antibodies recognizing the CD45RB
isoforms, the 23G2 clone had shown better binding on
splenic CD4 T cells (41). Since these were the cells we were
focusing on, we chose this antibody for all FACSÒ and
Western blot studies, conceding the fact that this antibody
would be specific to only a major subset of all CD45 iso-
forms. Fig. 11 shows that CD43 and CD45(exon B) coded
isoforms are sialomucins, since OSGPase treatment of both
CD4 and CD8 T cell surfaces almost completely destroys
their binding to the respective antibodies. This was further
confirmed by Western blot analysis of T cell membrane pro-
tein extracts treated with or without OSGPase, using anti-
CD43 and anti-CD45RB antibodies (data not shown). These
results are in agreement with earlier reports using methods
such as Western blots and/or FACSÒ analysis that describe
loss of CD43 recognition with OSGPase treatment (21)
and CD45RB epitopes by O-glycanase (40) or OSGPase
digestions (21). As evaluated by mean fluorescence inten-
sity of staining at varying dilutions of the antibodies, ex-
pression of these cell surface glycoproteins actually showed
higher levels of both CD43 and CD45R(exonB) contain-
ing isoforms on CD8 T cells than on CD4 cells (data not
shown). This observation is consistent with earlier results
using the same anti-CD43 S7 clone (43) and anti-CD45RB
(41). The data in Fig. 11 shows the relative abundance of
these glycoproteins on CD8 T cells in comparison to CD4
T cells at saturating levels of antibodies. Thus, the differ-
ences in sialomucin 9-O-acetylation is not due to differ-
ences in the levels of expression of the parent molecules
between CD4 and CD8 cells.
Western blot analyses of membrane proteins isolated
from total splenic mononuclear cells with the CHE-FcD
probe reveals several high molecular mass proteins that are
9-O-acetylated (Fig. 12). The specificity of recognition is
confirmed by the absence of any binding with the CHE-Fc
at similar concentration (data not shown). Pre-incubation
of the proteins with OSGPase destroys all the positive bands,
confirming that sialomucins are the major 9-O-acetylated
glycoproteins in these cells. Two of the major bands coin-
cided in molecular mass with that expected for CD45RB
and CD43. To evaluate this matter further, 9-O-acetylated
glycoproteins were precipitated from the total membrane
protein extracts using CHE-FcD bound to protein A–Sepha-
rose via its human IgG Fc tail. The CHE-Fc protein was
used as a control for any nonspecific precipitation. The
bound proteins were separated on a reducing SDS-PAGE
gel, transferred to nitrocellulose membranes and probed with
monoclonal antibodies recognising CD43 and CD45R
(exon B) isoforms. Fig. 12 demonstrates that the proteins
precipitated by CHE-FcD include molecules recognized by
anti-CD43 and by anti-CD45RB, that comigrate at the
same position with bands from total membrane proteins
recognized by the same antibodies. The weaker intensity of
the bands reflects the lower amounts of CD43 and CD45
Figure 8. 9-O-acetylated gangliosides are present in purified lipid ex-
tracts from CD4 T cells. Lipid extracts containing gangliosides from rest-
ing or activated CD4 cells were dried on to 96-well flat-bottomed plates
and CHE-FcD was allowed to bind with or without base treatment (0.1 N
sodium hydroxide for 15 min) to remove 9-O-acetyl groups. Binding was
detected with HRPO-conjugated second antibody and substrate. Results
shown are mean values from triplicates.
Figure 9. CHE-FcD does not affect T cell activation mediated by
PMA or by cross-linking with anti-CD3 antibodies. Total cells from
mouse lymph nodes were activated with varying amounts of PMA, or by
cross-linking with increasing amounts of anti-CD3 antibody. [3H]thymi-
dine incorporation into the cells measured the proliferative response of
the T cells. The effect of adding CHE-FcD or CHE-Fc in solution (final
50 mg/ml in all the wells) on the dose-response curve was plotted. Values
represent the mean of triplicate values. Background values for sham
treated cells were consistently lower than the smallest stimulating dose
(not shown).2006 9-O-acetylation in CD4 Cells
present in the immunoprecipitates (the precipitation was
not complete, data not shown). While the anti-CD45RB
gives the expected band of 190 kD (and some weaker bands
above), anti-CD43 detects a band migrating slightly below
the bulk population of molecules. This might be due to dif-
ferential mobilities of different CD43 glycoforms (43). The
bright band seen at z120 kD with the CD43 probe is non-
specific, since it was present on blots probed with alkaline-
phosphatase conjugated neutravidin alone, and also with the
CD45RB probe (data not shown). Upon probing the ma-
terial precipitated with CHE-FcD, and comparing the pro-
file with the CHE-FcD Western blot from the untreated
total protein extracts, it was clear that not all 9-O-acety-
lated glycoproteins were precipitated (data not shown); this
may be due to the fact that only a single round of depletion
was done or be due to the differential affinity of CHE-FcD
for various 9-O-acetylated proteins. Regardless, it is evident
from these data that CD43 and CD45(exonB) are among
the cell surface mucins that are 9-O-acetylated.
9-O-Acetylation on CD4 Cells Does Not Block CD22
Ligands. Earlier studies in our lab showed that 9-O-acety-
lation of sialic acids could mask the binding of recombinant
soluble CD22 (CD22Rg) to its ligands on some cells in
murine lymphoid organs (16). We found high amounts of
CD22Rg ligands on peripheral T cells and on CD41 and
CD81 SP thymocytes, and lower amounts on immature
thymocytes by flow cytometry (data not shown). Treat-
ment with CHE-Fc did not significantly increase the bind-
ing of CD22Rg to either mature peripheral CD4 cells or to
CD41 SP thymocytes (data not shown). This result is con-
sistent with the fact that most of the 9-O-acetylated glyco-
proteins on CD4 cells have mucin type O-linked structures
which are unlikely to carry the Sia a2-6Galb1-4 GlcNAc
sequence typical of CD22 ligands (44).
Figure 10. Sialomucins on
CD8 T cells can mask the recogni-
tion of 9-O-acetylated ganglio-
sides by CHE-FcD probe. (A)
Mouse spleen cells were stained
with CHE-FcD before or after
OSGPase or trypsin treatment
and staining profiles were traced
from gated CD4 and CD8 sub-
populations. Trypsin treatment
was done on CD4 and CD8 T
cells that were pre-sorted on a
FACSorterÒ. Loss of binding of
anti-Mel14 was a positive con-
trol for trypsinization (data not
shown). (B) Mouse thymocytes
were treated with OSGPase as
described earlier, washed and
stained with anti-CD4, CD8,
and CHE-FcD. Sham treated
cells were incubated with an
equal volume of buffer under
identical conditions. 100,000 live
events were acquired and CD4
and CD8 SP cells were gated
from a CD4/CD8 dot plot.
CHE-FcD binding within those
populations was plotted in the
histograms. The dotted line
shows background staining with
the second antibody.
Figure 11. CD43 and CD45RB are sialomucins expressed on both
CD8 cells and on CD4 cells. Freshly isolated mouse splenic lymphocytes
were incubated with OSGPase or with buffer alone, under identical con-
ditions. This was followed by three-color staining with anti-CD4, CD8,
and either anti-CD43 (S7) or CD45RB (23G2) at dilutions of 5 mg/ml.
The mean fluorescence intensity of staining on gated populations of CD4
and CD8 T cells was determined on a FACScanÒ.2007 Krishna and Varki
Discussion
Each type of cell has its own unique surface signature de-
termined by its glycosylated molecules. While sialic acids
with different a-ketosidic linkages from the 2- position to
the underlying glycoconjugate can confer a fair degree of
diversity, modifications of the sialic acids enhance this di-
versity further. Until recently, 9-O-acetylated sialic acids were
considered as rare oddities among the plethora of glycosy-
lated structures found in mammalian systems. It is now
known that they occur in several tissues of neuroectoder-
mal and mesenchymal descent (2). Studies such as in situ
histochemistry using specific probes indicate a temporal and
spatial pattern of regulation of 9-O-acetylation in develop-
ing tissues (3, 8, 9, 45–48). On a given cell type, 9-O-acet-
ylation tends to be non-randomly distributed with respect
to both the type of cell surface glycoconjugate (49), as well
with regard to the type of sialic acid linkage on a given gly-
coconjugate (50). Such data suggest specific roles for these
modifications in cell–cell recognition events inherent to
tissue organization and/or development.
Most descriptions of 9-O-acetylation have been based on
chemical analyses or on the binding of certain highly spe-
cific monoclonal antibodies that also recognize other details
of the underlying molecules. Earlier studies showed by in-
direct methods that mouse thymocytes might have 9-O-
acetylated sialic acids (51). It was also reported that T cells
from patients with various malignancies had O-acetylated
sialic acids (52, 53) and that 9-O-acetylation was present on
pig lymphocytes (54). However, the extraction methods used
could not specifically distinguish cell surface 9-O-acetyla-
tion. Other assays involved the use of intact influenza C
virions that specifically recognize 9-O-acetylated sialic acids
(18, 55). This approach is limited by the purity and stability
of the virus preparations and a relatively high background.
The availability of a soluble recombinant chimera (CHE-
FcD) derived from influenza C and its versatility in a vari-
ety of in vitro assays (3) makes it possible to look for 9-O-
acetylation on cell surfaces, irrespective of the underlying
sugar structure. We have studied here the cell surface ex-
pression of 9-O-acetylated sialic acids on intact fresh lym-
phocytes isolated from normal mice. While B lymphocytes
and CD8 T lymphocytes were heterogenous in their ex-
pression of low levels of 9-O-acetylated sialic acids, the sin-
gular pattern of high density expression on CD4 T cells led
to the current set of investigations.
In earlier work from our lab (16), CHE-FcD staining
was noted on medullary regions in histological sections from
the thymus. In keeping with this, we show that the acquisi-
tion of the 9-O-acetylation phenotype occurs almost en-
tirely within a subset of PNA2 mature thymocytes. A low
percentage of thymocytes are positive yet highly heteroge-
nous in their cell surface density of 9-O-acetylation, with a
disproportionately higher percentage of CD41 SP cells and
CD42CD82 DN cells and a lower percentage of CD41
CD81 DP cells. Thus, it seems that 9-O-acetylation of Sia
on mucins must be very specifically regulated during T cell
ontogeny (Fig. 13). In this regard, it is notable that other
changes in glycosylation during maturation of thymocytes
have been demonstrated, including varying patterns of ex-
pression of four different glycosyltransferases on cells with
significant phenotypic and functional differences (56, 57).
Among the CD42CD82 DN thymocytes, 35–40% have
low level expression of surface 9-O-acetylation. These
constitute only 2–3% of total thymocytes (58), and are het-
erogenous in the expression of several markers such as HSA,
CD44 (Pgp-1), CD25 (interleukin 2 receptor a chain),
Mel14, CD5, and c-kit. During this stage, the TCR-b lo-
cus undergoes rearrangement and cells that undergo pro-
ductive rearrangement are likely selected for further pro-
gress to the DP stage characterized by increasing surface
expression of TCR. During the transition from DN to DP
stage, thymocytes undergo several rounds of proliferation,
upregulate TCR-a rearrangement, stop TCR-b rearrange-
ment, and begin to turn on CD4 and CD8 expression.
Since we did not do a full phenotypic characterization of
Figure 12. CD43 and CD45R
(exonB) are among the 9-O-
acetylated membrane mucins in
splenic cells. The left panel
shows a Western blot of splenic
lymphocyte membrane proteins
(15 mg each lane) probed with
CHE-FcD (at 48C) with (lane 1)
or without (lane 2) prior treat-
ment of the proteins with OSGP-
ase. The right panel shows a
Western blot of total membrane
proteins, proteins precipitated
by CHE-FcD, and CHE-Fc
controls, each probed with anti-
CD43 and anti-CD45RB mono-
clonal antibodies as indicated.
The expected positions of
CD45RB (z190 kD) and CD43
(z115 kD) are indicated in each panel. The relatively bright band just above 115 kD in the right lanes of the right panel is nonspecific, since it was also
seen on probing with the alkaline phosphatase conjugated secondary reagent alone.2008 9-O-acetylation in CD4 Cells
the 9-O-acetyl1 DN cells, it is unclear whether these rep-
resent the precursors entering the thymus or a relatively
more mature subset.
The conspicuous upregulation of cell surface mucin
9-O-acetylation as thymocytes mature to CD41CD82
stage from the DP stage establishes this as a novel marker
identifying cells committed to the CD4 lineage (Figs. 13 and
14). In contrast, there is only a small increase in 9-O-acety-
lation on the CD81 SP cells, and this is not found on mu-
cins. During lineage commitment, DP thymocytes undergo
several sequential changes in expression of CD69, HSA,
and CD5. CD41 thymocytes that are CD691CHE-FcD2
represent cells that are still in the DP stage. Thymocytes
with low amounts of 9-O-acetylation are either CD691 or
CD692 suggesting the 9-O-acetylation phenotype of the
maturing CD41 cells is not specifically associated with this
early activation marker. A significant fraction of cells with
high 9-O-acetylation that must be CD41 SP cells seem to
have lost their CD69 expression, which fits in with their
expected downregulation on mature SP thymocytes. A
strong correlation of CD5hiTCRhiHSA2 pattern of expres-
sion with increasing surface 9-O-acetylation suggests that
O-acetylation identifies cells that have successfully been se-
lected and are on their way to becoming mature cells.
Fewer CD41 SP thymocytes are 9-O-acetylated as com-
pared to peripheral resting CD4 T cells. It is unclear if the
increase in CD41 cell 9-O-acetylation occurs at a periph-
eral location after emigration from the thymus, or if 9-O-
acetylhi CD41 SP cells are selectively exported from the
thymus. Functionally distinct subpopulations in CD4 SP
cells have been reported. One study showed the late CD4hi
thymocytes were functionally more mature than their im-
mediate precursors in several assays. They were able to col-
onize and expand in the peripheral lymphoid organs while
the CD4hi CD8lo subset had an obligatory requirement for
thymic microenvironment for further maturation (59). T cells
need to express homing molecules to enter the thymic
lymphatics or venules and exit at the corticomedullary junc-
tion. Such molecules must be expressed at the SP stage after
migration from the cortex through the corticomedullary
junction into the medulla where they would undergo neg-
ative selection. Surviving cells would, in addition to being
activated to divide, express homing receptors probably in-
fluenced by the local microenvironment. Assuming that a
critical threshold of homing receptors is required for a ma-
ture SP cell to emigrate, the progressive increase in cell sur-
face 9-O-acetylation in the CD4 SP lineage is a candidate
for subserving such a function.
Correlation of 9-O-acetylation on the peripheral CD4 T
cells with the expression of Mel14, Pgp-1, and CD45R(ex-
onB) indicates that this modification may be a marker for
naive T cells (28, 30). More than 95% of the naive CD4 T
cells and only z60% of the cells with a memory/activated
phenotype are 9-O-acetylated. This could be relevant ei-
ther to the specific recirculation patterns of these cells in
the mouse and/or recognition of some costimulatory mol-
ecule involved in T cell activation. Thus, 9-O-acetylated
sialic acids could recognize a specific ligand in the milieu
the T cells expose themselves to, or this modification could
mask recognition of the underlying carbohydrate structure
on T cells by an unknown receptor.
Fig. 13 summarizes the differential distribution of total
9-O-acetylated sialic acids on peripheral resting and acti-
vated CD4 T cells as detected by CHE-FcD. We know of
no other cell surface marker (other than CD4 itself) de-
scribed to date that specifically identifies the murine CD4
lineage. There have been studies showing higher expression
of some specific markers in the CD8 lineage, including
CD27 (60), CD45RB and RC isoforms (41), an epitope de-
pendent upon a post translational modification of CD45RB
Figure 13. Expression of 9-O-
acetylated sialic acids during T
cell ontogeny in the adult thy-
mus and on peripheral T cells.
This figure summarizes the dis-
tribution of 9-O-acetylated
sialic acids detected by CHE-
FcD on developing and on pe-
ripheral resting and activated T
cells. Varying intensities of
CHE-FcD binding are shown as
low (lo), intermediate (int) and
high (hi) along with a representa-
tive percentage of positive cells.
Note that while z40% of
CD42CD82 DN cells are 9-O-
acetyllo1, the phenotype of the
cells that actually progress to a
DP stage is not defined by our
current data. Also note that the
probe may not detect all ganglio-
side-bound 9-O-acetyl Sias (see
Fig. 14 and Discussion).2009 Krishna and Varki
and recognized by a monoclonal antibody CZ-1 (61), and
the 130-kD isoform of CD43 (43). The susceptibility of
the 9-O-acetylated glycoconjugates to the various enzyme
treatments suggests that most 9-O-acetylated thymocytes
have both 9-O-acetylated glycoproteins and gangliosides.
In contrast to the naive population where mucins are the
major carriers of 9-O-acetylation, in vitro activated CD4 T
cells appear to carry them primarily on protease-resistant
molecules (presumably gangliosides). Although there is a
substantial decrease in the mean density of 9-O-acetylation
on the activated cells, there is no significant difference in
the percentage of cells that are 9-O-acetylated. The pres-
ence of 9-O-acetylated gangliosides in the resting and acti-
vated CD4 T cells was confirmed in an ELISA using the
CHE-FcD. Further studies will be needed to define their
precise structure.
In addition to differences in the levels of 9-O-acetyla-
tion, CD4 and CD8 T cells also differ in their distribution
of O-acetylation on glycoconjugate classes. Although sialo-
mucins are the predominant 9-O-acetylated molecules on
CD4 T cells, these do not seem to be O-acetylated in the
case of CD8 T cells. This is not due to a quantitative differ-
ence in the amount of cell surface mucins, if anything, the
cell surface densities of two prominent sialomucins CD43
and CD45 (exon B isoforms) on CD8 cells are actually
higher than on CD4 T cells. Because of their rod-like rigid
structure, mucin molecules on both CD4 and CD8 T cells
could physically restrict the binding of CHE-FcD to the
O-acetylated gangliosides that are closer to the cell mem-
brane. Indeed, such an unmasking effect of OSGPase and
trypsin on CHE-FcD binding is particularly obvious on the
CD8 T cells. It is unclear how two developmentally closely
related cell types differ so radically in this sialic acid modifi-
cation. It might be due to differences in the regulation of
O-acetyltransferase gene expression or in the underlying
sialic acid linkages on the same mucin molecules between
the cell types.
It must be re-emphasized that not all O-linked sialogly-
coproteins get indiscriminately digested by OSGPase. Rather,
this enzyme specifically recognizes clustered sialic acid resi-
dues on O-linked glycans and cleaves the peptide bonds
close to the O-linked structures. Thus, while the CD8 mole-
cule itself is modified by O-linked glycosylation, it is resis-
tant to this protease, because the sugar chains are not clus-
tered. Fig. 14 summarizes the concept evolving from our
observations. Recognition of T cell surface gangliosides by
a soluble or a neighboring cell surface receptor might be
modulated by expression of mucin-like structures on T cells.
These mucins may or may not themselves bear a similar
carbohydrate epitope to that carried on the gangliosides.
With respect to 9-O-acetylation, this attribute is so well
demarcated between CD4 and CD8 cells that it might be
of some relevance to their biology. Although no well-defined
receptors for 9-O-acetylated glycoconjugates have been doc-
umented, such a masking phenomenon in vivo could, in
principle, prevent the recognition of 9-O-acetylated gan-
gliosides on resting T cells. Furthermore, it is clear from
our data from activated CD4 T cells this masking can be
modulated by the state of T cell differentiation. Assuming
there might be differences in physiological consequence
mediated by receptors recognizing 9-O-acetylated sialic ac-
ids on sialomucins and gangliosides, such a masking on
CD4 cells could be biologically relevant. Regardless of
their biological significance, these results underscore the
possibility that macromolecular probes for cell surface gly-
colipids may fail to detect their ligands because of shielding
by the larger sialomucins on the same surface (62, 63).
Our results also demonstrate 9-O-acetylation on two
well characterized sialomucins of T cells, CD43 and CD45.
CD43 (leukosialin) is a major cell surface glycoprotein on
T cells and is also present on cells of erythroid and myeloid
lineages. It is heavily glycosylated and the O-glycans at-
tached to it can vary with both the cell type and within
T cells based on their state of differentiation (32, 64). Dif-
ferences in the expression of its two major glycoforms 115
Figure 14. Model depicting the likely differential distribution of 9-O-
acetylated sialoglycoconjugates between resting peripheral CD4 and CD8
T cells. Sialomucins are present on both CD8 and CD4 cells, but are only
9-O-acetylated in the latter. Cell surface sialomucin molecules usually have
a rod like extended conformation and a high negative charge, and appears
to prevent CHE-FcD access to O-acetylated glycolipids (gangliosides)
that are much closer to the cell surface membrane. OSGPase recognizes
sialylated clustered O-linked glycans and cleaves the adjacent polypeptide
backbone, thus unmasking recognition of the enzyme-resistant O-acety-
lated gangliosides by the CHE-FcD probe.2010 9-O-acetylation in CD4 Cells
and the 130-kD species, have been shown between CD4
and CD8 T cells (43, 65). Our results suggest that 9-O-
acetylation of CD43 occurs differently on CD4 and CD8 T
cells. In this regard, it is interesting to note that the expres-
sion of the 130-kD isoform of CD43 shows an inverse cor-
relation with 9-O-acetylation; it is preferentially upregu-
lated on thymocytes committed to CD8 SP cells while being
low on CD4 SP thymocytes, and then prevails at high lev-
els on most peripheral CD8 T and lower levels on about
20% of CD4 T cells (43). Furthermore the 130-kD isoform
is markedly upregulated on human CD4 T cells upon acti-
vation. A thorough glycosylation analysis of the two mu-
rine CD43 isoforms needs to be done before one can spec-
ulate on how this could affect 9-O-acetylation on sialic acids.
CD45 is a family of high molecular weight glycoproteins
with various isoforms resulting from differential splicing of
exons 4, 5, and 6. All three exons code for regions rich in
O-glycosylated linkages (31, 40). While these isoforms can
differentially regulate T cell receptor signalling (66, 67), it
is not clear what role the carbohydrates play; neither is it
certain if there are any specific glycosylation differences on
CD45 molecules between naive CD4 and CD8 T cells. Al-
though we demonstrate 9-O-acetylation on the exon B spe-
cific isoforms it is possible this may be differentially glycosy-
lated between CD4 and CD8 T cells.
9-O-acetylation of sialic acids has been studied by others
in human lymphoid tissue. Using intact influenza C virus,
uncharacterized 9-O-acetylated glycoproteins have been
demonstrated by Western blots derived from human T cells
(55). Human peripheral blood T lymphocytes are also posi-
tive for the marker CD60, which represents GD3-related
gangliosides with 9-O-acetylation (33, 37). This antibody
binds to z25% of normal circulating human T lympho-
cytes and to most T cells infiltrating psoriatic skin lesions
and the synovial fluid space in rheumatoid arthritis (68, 69).
In patients with cutaneous T cell lymphoma, a majority of
circulating T cells and in dermal lesions were also positive
for this marker (70). Staining of mouse T cells with specific
antibodies for 9-O-acetylated GD3 did not give any positive
results. Thus, while 9-O-acetylation of Sia appears com-
mon to human and murine lymphocytes, it must be carried
on distinct glycolipids. Interestingly, most reported gangli-
osides in mouse T cells such as GD1a and GD1a arise from
the a or a series biosynthetic pathways (71, 72) and there is
no evidence for GD3, or any other member from the b se-
ries pathway. Recently, the presence of an unique ganglio-
side GD1c sharing the same terminal trisaccharide with GD3
has been identified by mAbs 3G11 (36) and YK-3 (73) on
mouse T cells with a preference for cells with a Th1 pheno-
type (73). It is possible that this structure is the functional
homologue of GD3 seen on human peripheral T cells. Un-
fortunately, there is no antibody currently available against
9-O-acetylated GD1c. It must also be remembered that most
sialic acids in the mouse have a N-glycolyl group attached
to the fifth carbon atom instead of the N-acetyl group
found in humans (1); this change can also influence recog-
nition by antibodies.
Several reports suggest that 9-O-acetylated CD60 epi-
topes on human T cells might serve in an alternate func-
tional activation pathway for T cells compartmentalized in
lesions of psoriasis and arthritis (37, 39, 68, 69). A mAb U5
preferentially recognizing 7-O-acetylated-GD3 on human
CD4 and CD8 T cells could elicit a even stronger prolifer-
ative response from these cells (74). Since mouse peripheral
T cells showed no evidence of 9-O-acetyl-GD3, we studied
CD4 T cells activation with bound or soluble forms of
CHE-FcD that would cross-link any 9-O-acetylated cell
surface molecule. We also looked for any potentiation of
PMA induced mitogenicity of CD4 T cells as reported ear-
lier with CD60 antibodies on human T cells (37–39).
While we did not see activation, this could be because
CHE-FcD binding to sialomucins is blocking access to gly-
colipids. There was also no effect in potentiating anti-
CD3–mediated T cell activation (Fig. 9). Since CHE-FcD
binds to any cell surface glycoconjugate bearing 9-O-acety-
lated sialic acids it might be hard to assess the effect of si-
multaneous binding to a variety of different molecules on
T cell activation. A specific mAb directed against the 9-O-
Ac-gangliosides in murine T cells would be needed to
make a valid comparison with CD60 activation in human
T cells.
The finding of 9-O-acetylated sialic acids on mouse T cells
underscores the widespread yet selective expression of this
unique modification on sialic acids. Several factors could
regulate the extent of 9-O-acetylation of sialic acids. An
earlier study demonstrated 9-O-acetylation on murine eryth-
rocyte sialic acids could be regulated by an autosomal dom-
inant gene and its expression can thus depend on the ge-
netic background of the animal being studied (14). Our
group recently reported 9-O-acetylation on Chinese ham-
ster ovary cells was dependent on the availability of the
correct linkage of the sialic acid to the underlying sugar
chain (50). Such observations coupled with the present
findings are strong predictors for a functional role of 9-O-
acetylated sialic acids. It remains to be seen how the re-
markably different 9-O-acetylation of sialomucins on mouse
CD4 and CD8 cells might influence the in vivo biology of
those cells.
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